130 related articles for article (PubMed ID: 30201516)
1. Rational design and development of a stable liquid formulation of riluzole and its pharmacokinetic evaluation after oral and IV administrations in rats.
Sarkar M; Grossman RG; Toups EG; Chow DS
Eur J Pharm Sci; 2018 Dec; 125():1-10. PubMed ID: 30201516
[TBL] [Abstract][Full Text] [Related]
2. Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug.
van der Vossen AC; van der Velde I; Smeets OS; Postma DJ; Eckhardt M; Vermes A; Koch BC; Vulto AG; Hanff LM
Eur J Pharm Sci; 2017 Mar; 100():205-210. PubMed ID: 28126558
[TBL] [Abstract][Full Text] [Related]
3. Development of a liquid formulation of poorly water-soluble isosteviol sodium using the co-solvent technology.
Lai W; Kang Q; Zou C; Li Q; Sun H; Tan W
Pharm Dev Technol; 2017 Mar; 22(2):275-282. PubMed ID: 27557399
[TBL] [Abstract][Full Text] [Related]
4. Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis.
Dyer AM; Smith A
Drug Des Devel Ther; 2017; 11():59-64. PubMed ID: 28053507
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of riluzole in acute spinal cord injury.
Chow DS; Teng Y; Toups EG; Aarabi B; Harrop JS; Shaffrey CI; Johnson MM; Boakye M; Frankowski RF; Fehlings MG; Grossman RG
J Neurosurg Spine; 2012 Sep; 17(1 Suppl):129-40. PubMed ID: 22985379
[TBL] [Abstract][Full Text] [Related]
6. Nanoemulsions for Intranasal Delivery of Riluzole to Improve Brain Bioavailability: Formulation Development and Pharmacokinetic Studies.
Parikh RH; Patel RJ
Curr Drug Deliv; 2016; 13(7):1130-1143. PubMed ID: 26638977
[TBL] [Abstract][Full Text] [Related]
7. A novel intravenous vehicle for preclinical cardiovascular screening of small molecule drug candidates in rat.
Banfor PN; Gintant GA; Lipari JM; Zocharski PD
J Pharmacol Toxicol Methods; 2016; 82():62-67. PubMed ID: 27432021
[TBL] [Abstract][Full Text] [Related]
8. Development and pharmacokinetic evaluation of a curcumin co-solvent formulation.
John MK; Xie H; Bell EC; Liang D
Anticancer Res; 2013 Oct; 33(10):4285-91. PubMed ID: 24122994
[TBL] [Abstract][Full Text] [Related]
9. Antinociceptive effect of riluzole in rats with neuropathic spinal cord injury pain.
Hama A; Sagen J
J Neurotrauma; 2011 Jan; 28(1):127-34. PubMed ID: 20954888
[TBL] [Abstract][Full Text] [Related]
10. Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems.
Cirri M; Mura P; Mora PC
Int J Pharm; 2007 Aug; 340(1-2):84-91. PubMed ID: 17531411
[TBL] [Abstract][Full Text] [Related]
11. Assessment of toxicity and tolerability of a combination vehicle; 5% Pharmasolve, 45% Propylene glycol and 50% Polyethylene glycol 400 in rats following repeated intravenous administration.
Pandey SK; Goyal VK; Nalge P; Are P; Vincent S; Nirogi R
Regul Toxicol Pharmacol; 2017 Dec; 91():103-108. PubMed ID: 29066335
[TBL] [Abstract][Full Text] [Related]
12. Intranasal spray formulation containing rizatriptan benzoate for the treatment of migraine.
Chokshi A; Vaishya R; Inavolu R; Potta T
Int J Pharm; 2019 Nov; 571():118702. PubMed ID: 31593810
[TBL] [Abstract][Full Text] [Related]
13. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
Chen C; Bujanover S; Kareht S; Rapoport AM
Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
[TBL] [Abstract][Full Text] [Related]
14. Single- and multiple-dose pharmacokinetics of riluzole in white subjects.
Le Liboux A; Lefebvre P; Le Roux Y; Truffinet P; Aubeneau M; Kirkesseli S; Montay G
J Clin Pharmacol; 1997 Sep; 37(9):820-7. PubMed ID: 9549636
[TBL] [Abstract][Full Text] [Related]
15. Solvent-based formulations for intravenous mouse pharmacokinetic studies: tolerability and recommended solvent dose limits.
Thackaberry EA; Wang X; Schweiger M; Messick K; Valle N; Dean B; Sambrone A; Bowman T; Xie M
Xenobiotica; 2014 Mar; 44(3):235-41. PubMed ID: 24138296
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers.
Le Liboux A; Cachia JP; Kirkesseli S; Gautier JY; Guimart C; Montay G; Peeters PA; Groen E; Jonkman JH; Wemer J
J Clin Pharmacol; 1999 May; 39(5):480-6. PubMed ID: 10234595
[TBL] [Abstract][Full Text] [Related]
17. The impact of co-solvents and the composition of experimental formulations on the pump rate of the ALZET osmotic pump.
Bittner B; Thelly T; Isel H; Mountfield RJ
Int J Pharm; 2000 Sep; 205(1-2):195-8. PubMed ID: 11000556
[TBL] [Abstract][Full Text] [Related]
18. An Open-Label, Randomized Bioavailability Study of Alternative Methods of Oral Administration of Naloxegol in Healthy Subjects.
Bui K; Birmingham B; Diva U; Berger B
Clin Pharmacol Drug Dev; 2017 Jul; 6(4):420-427. PubMed ID: 28127938
[TBL] [Abstract][Full Text] [Related]
19. Association of riluzole and dantrolene improves significant recovery after acute spinal cord injury in rats.
Martins BC; Torres BBJ; de Oliveira KM; Lavor MS; Osório CM; Fukushima FB; Rosado IR; de Melo EG
Spine J; 2018 Mar; 18(3):532-539. PubMed ID: 29155254
[TBL] [Abstract][Full Text] [Related]
20. Development of a stable oral liquid dosage form of spironolactone.
Pramar Y; Das Gupta V; Bethea C
J Clin Pharm Ther; 1992 Aug; 17(4):245-8. PubMed ID: 1429919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
